2 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Approved WMOCompleted
Primary• To compare the anticholinergic side effects between repeated intravaginal administration of oxybutynin with the vaginal MedRing device and repeated oral administrationSecondary• To explore the pharmacokinetics of oxybutynin and its main…